Kangstem Biotech Co., Ltd.

A217730

KR7217730001

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 12/06/2024 BST			5-day change	1st Jan Change
3,375 ^KRW	+1.50%		+22.95%	+40.92%

05-09	HLB bioStep Co.,Ltd. announced that it has received KRW 1.438165744 billion in funding from Kangstem Biotech Co., Ltd.	CI
04-25	An undisclosed buyer agreed to acquire a 24.27% stake in Croen Inc. from Kangstem Biotech Co., Ltd. for KRW 2.8 billion	CI

Kang Stem Biotech Co., Ltd. has filed an IPO in the amount of KRW 20.00 billion.

September 22, 2015 at 05:00 am

Kang Stem Biotech Co., Ltd. has filed an IPO in the amount of KRW 20.00 billion.

Offer Details:
Security Type: Common Stock
Offered: 2000000
Price/Range: 8000.00 to 10000.00

Latest news about Kangstem Biotech Co., Ltd.

HLB bioStep Co.,Ltd. announced that it has received KRW 1.438165744 billion in funding from Kangstem Biotech Co., Ltd.	05-08	CI
An undisclosed buyer agreed to acquire a 24.27% stake in Croen Inc. from Kangstem Biotech Co., Ltd. for KRW 2.8 billion	04-24	CI
Kangstem Biotech Co., Ltd.(KOSDAQ:A217730) dropped from S&P Global BMI Index	18/09/23	CI
Kang Stem Biotech to Raise 35.1 Billion Won via Shares Issuance; Shares Plunge 30%	14/08/23	MT
Kangstem Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Kang Stem Biotech Co., Ltd. announced that it has received KRW 47.99962221 billion in funding from a group of investors	10/07/19	CI
Kang Stem Biotech Co., Ltd. announced that it expects to receive KRW 47.99962221 billion in funding from a group of investors	02/07/19	CI
Kang Stem Biotech Co., Ltd. cancelled the acquisition of 60% stake in Croen Inc.	19/04/18	CI
Kang Stem Biotech Co., Ltd. announced that it has received KRW 1.40 billion in funding	27/04/17	CI
Kang Stem Biotech Co., Ltd. agreed to acquire a 60% stake in Croen Inc. for KRW 2.7 billion.	19/04/17	CI
Kang Stem Biotech Co., Ltd. announced that it expects to receive KRW 1.40 billion in funding	19/04/17	CI
Kang Stem Biotech Co., Ltd. announced that it has received KRW 30 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, LIG Investment & Securities Co., Ltd., Investment Arm, and other investors	07/09/16	CI
Kang Stem Biotech Co., Ltd. announced that it expects to receive KRW 30 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, LIG Investment & Securities Co., Ltd., Investment Arm, and other investors	06/09/16	CI
ORIG3N, Inc and Kangstem Biotech Announce Collaboration to Study Neural Stem Cells	21/06/16	CI
Lutronic Corporation cancelled the sale of 4.11% stake in Kang Stem Biotech Co., Ltd.	06/05/16	CI
Kang Stem Biotech Co., Ltd.(KOSDAQ:A217730) added to S&P Global BMI Index	21/03/16	CI
Kang Stem Biotech Co., Ltd. has completed an IPO in the amount of KRW 12.00 billion.	16/12/15	CI
Kang Stem Biotech Co., Ltd. has filed an IPO in the amount of KRW 20.00 billion.	22/09/15	CI
Lutronic Corporation signed a contract to sell 4.11% stake in Kang Stem Biotech Co., Ltd. for KRW 2.4 billion.	07/05/15	CI

Chart Kangstem Biotech Co., Ltd.

Duration

Period

More charts

Kang Stem Biotech Co., LTD is a Korea-based company mainly engaged in the development of pharmaceutical products. The Company's product portfolio consists of stem cell therapy products including Furestem-AD which used for treating atopic dermatitis, Furestem-RA which used for treating rheumatoid arthritis, Furestem-CD which used for treating crohnâs disease, stem cell conditioned medias which used as raw materials of cosmetics including umbilical cord blood-derived stem cell conditioned medias (USC-CMs) and others and stem cell culture medias including KSB-3 Complete Kit and others. The Company distributes its products within domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KANGSTEM BIOTECH CO., LTD.	+40.92%	137M
MODERNA, INC.	+46.03%	55.66B
IQVIA HOLDINGS INC.	-7.53%	38.98B
LONZA GROUP AG	+36.25%	38.8B
CELLTRION, INC.	-9.38%	27.32B
ICON PUBLIC LIMITED COMPANY	+12.31%	26.29B
ALNYLAM PHARMACEUTICALS, INC.	-16.38%	20.25B
UNITED THERAPEUTICS CORPORATION	+30.79%	12.76B
MEDPACE HOLDINGS, INC.	+28.57%	12.18B
BIO-TECHNE CORPORATION	-0.36%	12.12B

Other Biotechnology & Medical Research